The standard therapy to treat newly diagnosed MM (NDMM) patients is induction therapy based on quadruplets drug combination including anti-CD38 monoclonal antibody (mAb) followed by high-dose chemotherapy plus autologous stem cell transplant (ASCT) for young patients (3). This evidence concerns the gene CD38 and Miyoshi myopathy.